Drugs of porcine origin—A risk for patients with α-gal syndrome?

TY - JOUR

T1 - Drugs of porcine origin—A risk for patients with α-gal syndrome?

AU - Swiontek, Kyra

AU - Morisset, Martine

AU - Codreanu-Morel, Françoise

AU - Fischer, Jörg

AU - Mehlich, Jana

AU - Darsow, Ulf

AU - Petitpain, Nadine

AU - Biedermann, Tilo

AU - Ollert, Markus

AU - Eberlein, Bernadette

AU - Hilger, Christiane

N1 - Funding Information: This study was funded by the Ministry of Higher Education and Research and by a grant from Laboratoires Réunis , Luxembourg . Funding Information: Conflicts of interest: C. Hilger received technical support from BÜHLMANN Laboratories AG (Schönenbuch, Switzerland) and a grant from Laboratoires Réunis, Luxembourg. J. Mehlich and B. Eberlein received technical support from BÜHLMANN Laboratories AG and travel support from ALK-Abelló outside the submitted work. M. Ollert reports personal fees from Hycor Biomedical outside the submitted work. U. Darsow gave advice to or received an honorarium for talks or research grant from ALK-Abelló, Bencard, Meda, Novartis, and Sanofi-Regeneron outside the submitted work. T. Biedermann received nonfinancial support from BÜHLMANN Laboratories AG and gave advice to or got an honorarium for talks or research grant from ALK-Abelló, Astellas, Bencard, Biogen, Celgene, Janssen, Leo, Meda, Mylan, MSD, Novartis, Phadia-Thermo Fisher Scientific, and Sanofi-Regeneron outside the submitted work. N. Petitpain is involved without receiving personal grant in the coordination of an academic investigational study funded by a consortium of 15 companies marketing pholcodine (Alliance, Bell's Healthcare, Biocodex, Boots, Bouchara, Ernest Jackson, GlaxoSmithKline, Hepatoum, Medgenix, Pierre Fabre, Sanofi, T&R, Urgo, Vemedia, and Zambon). The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This study was funded by the Ministry of Higher Education and Research and by a grant from Laboratoires R?unis, Luxembourg.Conflicts of interest: C. Hilger received technical support from B?HLMANN Laboratories AG (Sch?nenbuch, Switzerland) and a grant from Laboratoires R?unis, Luxembourg. J. Mehlich and B. Eberlein received technical support from B?HLMANN Laboratories AG and travel support from ALK-Abell? outside the submitted work. M. Ollert reports personal fees from Hycor Biomedical outside the submitted work. U. Darsow gave advice to or received an honorarium for talks or research grant from ALK-Abell?, Bencard, Meda, Novartis, and Sanofi-Regeneron outside the submitted work. T. Biedermann received nonfinancial support from B?HLMANN Laboratories AG and gave advice to or got an honorarium for talks or research grant from ALK-Abell?, Astellas, Bencard, Biogen, Celgene, Janssen, Leo, Meda, Mylan, MSD, Novartis, Phadia-Thermo Fisher Scientific, and Sanofi-Regeneron outside the submitted work. N. Petitpain is involved without receiving personal grant in the coordination of an academic investigational study funded by a consortium of 15 companies marketing pholcodine (Alliance, Bell's Healthcare, Biocodex, Boots, Bouchara, Ernest Jackson, GlaxoSmithKline, Hepatoum, Medgenix, Pierre Fabre, Sanofi, T&R, Urgo, Vemedia, and Zambon). The rest of the authors declare that they have no relevant conflicts of interest. This study was funded by the Ministry of Higher Education and Research and by a grant from Laboratoires R?unis, Luxembourg. Conflicts of interest: C. Hilger received technical support from B?HLMANN Laboratories AG (Sch?nenbuch, Switzerland) and a grant from Laboratoires R?unis, Luxembourg. J. Mehlich and B. Eberlein received technical support from B?HLMANN Laboratories AG and travel support from ALK-Abell? outside the submitted work. M. Ollert reports personal fees from Hycor Biomedical outside the submitted work. U. Darsow gave advice to or received an honorarium for talks or research grant from ALK-Abell?, Bencard, Meda, Novartis, and Sanofi-Regeneron outside the submitted work. T. Biedermann received nonfinancial support from B?HLMANN Laboratories AG and gave advice to or got an honorarium for talks or research grant from ALK-Abell?, Astellas, Bencard, Biogen, Celgene, Janssen, Leo, Meda, Mylan, MSD, Novartis, Phadia-Thermo Fisher Scientific, and Sanofi-Regeneron outside the submitted work. N. Petitpain is involved without receiving personal grant in the coordination of an academic investigational study funded by a consortium of 15 companies marketing pholcodine (Alliance, Bell's Healthcare, Biocodex, Boots, Bouchara, Ernest Jackson, GlaxoSmithKline, Hepatoum, Medgenix, Pierre Fabre, Sanofi, T&R, Urgo, Vemedia, and Zambon). The rest of the authors declare that they have no relevant conflicts of interest. We thank Franziska Martin for her excellent technical support. We also thank Michael Schneider (B?HLMANN Laboratories AG, Sch?nenbuch, Switzerland) for support. This study was funded by the Ministry of Higher Education and Research and by a grant from Laboratoires R?unis, Luxembourg. Conflicts of interest: C. Hilger received technical support from B?HLMANN Laboratories AG (Sch?nenbuch, Switzerland) and a grant from Laboratoires R?unis, Luxembourg. J. Mehlich and B. Eberlein received technical support from B?HLMANN Laboratories AG and travel support from ALK-Abell? outside the submitted work. M. Ollert reports personal fees from Hycor Biomedical outside the submitted work. U. Darsow gave advice to or received an honorarium for talks or research grant from ALK-Abell?, Bencard, Meda, Novartis, and Sanofi-Regeneron outside the submitted work. T. Biedermann received nonfinancial support from B?HLMANN Laboratories AG and gave advice to or got an honorarium for talks or research grant from ALK-Abell?, Astellas, Bencard, Biogen, Celgene, Janssen, Leo, Meda, Mylan, MSD, Novartis, Phadia-Thermo Fisher Scientific, and Sanofi-Regeneron outside the submitted work. N. Petitpain is involved without receiving personal grant in the coordination of an academic investigational study funded by a consortium of 15 companies marketing pholcodine (Alliance, Bell's Healthcare, Biocodex, Boots, Bouchara, Ernest Jackson, GlaxoSmithKline, Hepatoum, Medgenix, Pierre Fabre, Sanofi, T&R, Urgo, Vemedia, and Zambon). The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2019/5/1

Y1 - 2019/5/1

UR - http://www.scopus.com/inward/record.url?scp=85059949205&partnerID=8YFLogxK

UR - https://pubmed.ncbi.nlm.nih.gov/30557715

U2 - 10.1016/j.jaip.2018.12.005

DO - 10.1016/j.jaip.2018.12.005

M3 - Article

C2 - 30557715

AN - SCOPUS:85059949205

SN - 2213-2198

VL - 7

SP - 1687-1690.e3

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 5

ER -